Current Issue


VOL 13 NO 4 • May/Jun 2022


This issue’s cover illustration depicts a single SARS-CoV-2 virus casting a long shadow on neutrophils and lymphocytes. Artwork by Alexandra Webber © 2022, DNA Illustrations, Inc., Asheville, North Carolina.


Editorial

Do You Employ Shared Decision-Making in Your Practice?

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, FAAN

Imagine this scenario: A patient is scheduled to see you for a routine follow-up appointment. You are co-managing this patient with a physician. In preparation for the encounter, you review the chart and note that the patient obtained surveillance labs and CT scans earlier in the week in preparat...


Research and Scholarship

Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling

Nada Alsuhebany,(1,2,3) BSPharm, PharmD, BCOP, Jamie Brown,(4) PharmD, MBA, Jacquelyne Echave,(5) and Ali McBride,(5) PharmD, MS, BCPS

Malignancy is the second leading cause of death in the United States and was attributed to 44.9% of all mortality in 2016 (Heron, 2016). The incidence of emergency department (ED) visits by cancer patients has grown over the past years and continues to do so (Delgado-Guay et al., 2015). In additi...


Research and Scholarship

Implementing a Clinical Decision Tool to Improve Oncologic Venous Thromboembolism Management

Jibran Majeed,(1,2) DNP, ACNP-BC, CCRN, Barbara S. Turner,(1) PhD, RN, FAAN, Deirdre Kelly,(2) ACNP-BC, Chester Poon,(2) Julie A. Thompson,(1) PhD, John Barrett,(3) DNP, FNP-BC, AGACNP-BC, and Gerald A. Soff,(4) MD

Venous thromboembolic (VTE) disease in cancer patients is associated with significant morbidity, mortality, and cost (Seroussi et al., 2019). Cancer patients are also at greater risk for hospitalization and bleeding compared with non-cancer patients (Frere et al., 2019; Nene & Coyne, 2017). P...


Review Article

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Matthew Waggoner,(1) MS, John Katsetos,(1) PA-C, Emilee Thomas,(1) MBA, MPH, PA-C, Ilene Galinsky,(2) BSN, MSN, ANP-C, and Heather Fox,(3) PA-C

Venetoclax (Venclexta) is a potent, selective, and orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a protein that is overexpressed in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML; Jia et al., 2008; Tzifi et al., 201...


Review Article

Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice

Kelley D. Mayden,(1) DNP, APRN-FNP, AOCNP®, John M. Kelton,(2) PharmD, Joanne C. Ryan,(2) PhD, RN, and Ali McBride,(3,4) PharmD, BCPS, BCOP

Biologics derived from living organisms comprise half of the pharmacologic market share in oncology (Konstantinidou et al., 2020). Manufacturing exact copies of any biologic is impossible, given their inherent variability (Congressional Research Service Report, 2019). Biosimilars are highly simil...


Practice Matters

COVID-19 Vaccine Effectiveness in Oncology Patients

Rachel La Costa, MPAS, PA-C

In 2019, a global pandemic emerged from a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), now a ubiquitous household term. COVID-19 has caused significant morbidity and mortality, resulting in nearly 1 million deat...


Prescriber's Corner

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma

Jessica Davis,(1) PharmD, BCOP, CPP, and Megan Wayman,(2) PharmD

Incidence rates of cutaneous melanoma have increased over the past few decades, currently accounting for 1% of all skin cancers. In 2022, an estimated 108,480 new cases will be diagnosed, and 11,990 people are expected to die of melanoma. Metastatic melanoma is associated with high mortality, wit...


Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.